PMID- 27772740
DCOM- 20170522
LR  - 20170916
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 370
DP  - 2016 Nov 15
TI  - Prolonged-release fampridine treatment improved subject-reported impact of
      multiple sclerosis: Item-level analysis of the MSIS-29.
PG  - 123-131
LID - S0022-510X(16)30543-3 [pii]
LID - 10.1016/j.jns.2016.08.052 [doi]
AB  - Prolonged-release (PR) fampridine is approved to treat walking impairment in
      persons with multiple sclerosis (MS); however, treatment benefits may extend
      beyond walking. MOBILE was a phase 2, 24-week, double-blind, placebo-controlled
      exploratory study to assess the impact of 10mg PR-fampridine twice daily versus
      placebo on several subject-assessed measures. This analysis evaluated the
      physical and psychological health outcomes of subjects with progressing or
      relapsing MS from individual items of the Multiple Sclerosis Impact Scale
      (MSIS-29). PR-fampridine treatment (n=68) resulted in greater improvements from
      baseline in the MSIS-29 physical (PHYS) and psychological (PSYCH) impact
      subscales, with differences of 89% and 148% in mean score reduction from baseline
      (n=64) at week 24 versus placebo, respectively. MSIS-29 item analysis showed that
      a higher percentage of PR-fampridine subjects had mean improvements in 16/20 PHYS
      and 6/9 PSYCH items versus placebo after 24weeks. Post hoc analysis of the
      12-item Multiple Sclerosis Walking Scale (MSWS-12) improver population
      (>/=8-point mean improvement) demonstrated differences in mean reductions from
      baseline of 97% and 111% in PR-fampridine MSIS-29 PHYS and PSYCH subscales versus
      the overall placebo group over 24weeks. A higher percentage of MSWS-12 improvers 
      treated with PR-fampridine showed mean improvements in 20/20 PHYS and 8/9 PSYCH
      items versus placebo at 24weeks. In conclusion, PR-fampridine resulted in
      physical and psychological benefits versus placebo, sustained over 24weeks.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Gasperini, Claudio
AU  - Gasperini C
AD  - Multiple Sclerosis Center, Department of Neurosciences, San Camillo-Forlanini
      Hospital, Rome, Italy. Electronic address:
FAU - Hupperts, Raymond
AU  - Hupperts R
AD  - Orbis Medical Center, Sittard-Geleen, The Netherlands.
FAU - Lycke, Jan
AU  - Lycke J
AD  - Institute of Neuroscience and Physiology, Department of Neuroscience, The
      Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital,
      Gothenburg, Sweden.
FAU - Short, Christine
AU  - Short C
AD  - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia Canada.
FAU - McNeill, Manjit
AU  - McNeill M
AD  - Biogen, Maidenhead, UK.
FAU - Zhong, John
AU  - Zhong J
AD  - Biogen, Cambridge, MA, USA.
FAU - Mehta, Lahar R
AU  - Mehta LR
AD  - Biogen, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160825
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Potassium Channel Blockers)
RN  - BH3B64OKL9 (4-Aminopyridine)
SB  - IM
MH  - 4-Aminopyridine/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Chronic Progressive/*drug therapy/physiopathology/psychology
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/physiopathology/psychology
MH  - Potassium Channel Blockers/*therapeutic use
MH  - Severity of Illness Index
MH  - Treatment Outcome
OT  - *MSIS-29
OT  - *MSWS-12
OT  - *Multiple sclerosis
OT  - *Patient-reported outcomes
OT  - *Prolonged-release fampridine
OT  - *Walking impairment
EDAT- 2016/10/25 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/03/09 00:00 [received]
PHST- 2016/08/19 00:00 [revised]
PHST- 2016/08/24 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - S0022-510X(16)30543-3 [pii]
AID - 10.1016/j.jns.2016.08.052 [doi]
PST - ppublish
SO  - J Neurol Sci. 2016 Nov 15;370:123-131. doi: 10.1016/j.jns.2016.08.052. Epub 2016 
      Aug 25.